Overview

Pneumagen is developing a glycan targeted intranasal therapy for the pan-viral treatment of infectious diseases of the respiratory tract.  Pneumagen has secured approximately £10m of funding and is advancing its lead product Neumifil into clinical trials in mid 2021. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and research and development capabilities.

Priority targets for Neumifil are those at high-risk from viral RTIs including front-line health professionals and the elderly, (especially those in care homes). Also those who are obese, diabetic or are more susceptible to respiratory infections including seasonal flu, such as people with chronic obstructive pulmonary disease and asthma.

Our team

Douglas Thomson, Chief Executive Officer

Douglas Thomson has significant international experience as CEO, Chairman, NXD and Business Development Director. He has led executive teams generating rapid value creation at companies such as 4D Pharma. Working with Thomas Engelen to deliver the Company’s strategic objectives, Douglas accesses an extensive network of industry experts and service providers to drive forward Pneumagen’s products and technologies. He has executed multiple commercial deals with biotechnology and pharmaceutical companies.

Dr David Howat, Development Director

David has run drug development in many small biotech/pharmaceutical companies working to tight timelines, most recently at Haoma Medica Ltd and previously at Evgen Plc. During these projects, he has managed the full width of the projects including CMC, safety toxicology and regulatory activities leading to First in Human clinical trial as well as more complex phase II trials involving multi-centre and international sites. This has also involved meetings with the regulatory authorities in the UK, Europe and the USA. The projects have required outsourced contracts for manufacturing, toxicology and clinical studies requiring excellent project management skills and the ability to navigate the regulatory environment to achieve the most rapid, cost effective and safe path to clinical trials.

Thomas Engelen, Non-executive Chairman

Thomas Engelen has a track record in creating value in Listed and in Private Equity backed investments in Life Sciences and Chemicals including financial and operational turn-around as part of MBO and MBI. Support to PE in Due Diligence in various European countries, Brazil and the USA on targets with Enterprise Value up to US$ 1 Billion. Current engagements include Chair at Innovatrain AG and Stan Chem International Ltd.

Professor Garry Taylor, Director and Chairman of the Scientific Advisory Board

Professor Garry Taylor was until recently, the Master of the University of St. Andrews, Scotland. A co- inventor of the CBM intellectual property, the ‘Taylor’ lab has a long history in studying the molecular mechanisms of proteins from respiratory pathogens and it is the work of his team that led to the CBM technology and products. Garry is a shareholder, director and advisor to the Company including chairing the Scientific Advisory Board.

Mark R. Bamforth, Non-executive Director

Mark Bamforth founded Arranta Bio to build the best-in-class microbiome contract development and manufacturing organization (CDMO), in May 2019. Arranta has process development and early clinical manufacturing in Florida and a late-stage manufacturing facility in Massachusetts.

Previously, Bamforth founded Brammer Bio, a best-in-class viral vector CDMO for cell and gene therapies. Brammer’s team grew from 110 in 2016 to over 600 in Florida and Massachusetts, at the time of its acquisition by Thermo Fisher Scientific in April 2019.  

In 2010, Bamforth founded a biologics CDMO, Gallus BioPharmaceuticals, and acquired a world-class facility and team in St. Louis, MO, with a commercial supply agreement with Janssen. Gallus tripled through organic growth and merging with Laureate Biopharma. Gallus was sold to DPx Holdings B.V. in 2014.

Bamforth previously spent 22 years in the UK and USA at Genzyme, latterly running the 12-site global manufacturing operation and a pharmaceutical CMO business and serving as a corporate officer for 9 years. He began his career as a petroleum engineer exploring for North Sea oil with Britoil, then as a chemical engineer in the whisky industry with Whitbread.

Bamforth serves on the boards of Avid Bioservices, Continuus Pharma, Pneumagen, Enterobiotix, MassBio, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.

Scientific Advisory Board

Professor Jürgen Haas

Professor Jürgen Haas is the Head of Infection Medicine and Professor for Viral Genomics at the University of Edinburgh. He is also an honorary NHS consultant Virologist at the Royal Infirmary Edinburgh. After undergraduate studies in Medicine and Biology, he performed postdoctoral trainings at Munich and Harvard University, followed by a medical specialist training in Microbiology at the Universities of Heidelberg and Munich. Before he joined the University of Edinburgh in 2006, he has been Associate Professor at the University of Munich.

Sir John Skehel

Sir John Skehel FRS FMedSci, is a world leader in influenza research for which he has received many awards. He headed the WHO Collaborating Centre for Reference and Research on Influenza and was Director of the National Institute of Medical Research in London for almost 20 years. He is currently Vice President and Biological Secretary of The Royal Society and an Emeritus professor at The Francis Crick Institute, London.

Dr Richard Webby

Dr Richard Webby is a Member of the Department of Infectious diseases at St Jude Children’s Research Hospital and Director of the World Health Organization Collaborating Centre for Studies on the Ecology of Influenza in Animals. He has a basic research program, funded by ALSAC, the fundraising arm of St Jude, and the US National Institutes of Health, that focuses on influenza viruses at the human-animal interface. His expertise is in influenza virology and he has substantial experience in in vivo and in vitro models of influenza virus replication, pathogenicity, and transmission.

Professor Moira Whyte

Professor Moira Whyte OBE FRCP FMedSci FRSE is the Sir John Crofton Professor of Respiratory Medicine at the University of Edinburgh. She is Vice-Principal and Head of the College of Medicine and Veterinary Science at the University of Edinburgh, and former Director of the Medical Research Council Centre for Inflammation Research.